Drug intelligence / Profile preview

gallium Ga 68 NOTA-DNA multivalent SGC8

Development stage: Preclinical
Lead developer: Hunan University
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

Gallium Ga 68 NOTA-DNA multivalent SGC8 is an experimental radiopharmaceutical designed for positron emission tomography (PET) imaging of malignancies that overexpress protein tyrosine kinase 7 (PTK7). The agent consists of the positron-emitting radioisotope Gallium-68 ($^{68}$Ga) chelated by NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and conjugated to a multivalent DNA scaffold containing multiple copies of the SGC8 aptamer. By utilizing a multivalent approach—often through DNA nanostructures like tetrahedrons or branched DNA—the tracer achieves significantly higher binding affinity and improved tumor retention compared to monovalent aptamer sequences. The SGC8 aptamer specifically targets the extracellular domain of PTK7, a cell surface pseudokinase frequently upregulated in T-cell acute lymphoblastic leukemia (T-ALL) and various solid tumors, making it a valuable biomarker for cancer diagnosis and staging.

Other names: 68Ga-labeled multivalent SGC8 DNA aptamerGallium-68 NOTA-conjugated multivalent SGC8 aptamerGallium68 NOTA-conjugated multivalent SGC8 aptamerGallium 68 NOTA-conjugated multivalent SGC8 aptamerGallium-68 NOTA-DNA multivalent SGC8Gallium68 NOTA-DNA multivalent SGC8Gallium 68 NOTA-DNA multivalent SGC8

Targets

PTK7 (Protein tyrosine kinase 7)

Beyond the preview

Go deeper on gallium Ga 68 NOTA-DNA multivalent SGC8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium Ga 68 NOTA-DNA multivalent SGC8.

Explore the full profile